" class="no-js "lang="en-US"> Steven Kelly - Medtech Alert
Wednesday, September 17, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Steven Kelly

Steven Kelly

About Steven Kelly

Steven Kelly joined Carisma Therapeutics in February 2018 bringing nearly thirty years of experience in Pharma/Biotech at all phases of the business across multiple therapeutic categories. Prior to joining Carisma, Mr. Kelly held a number of leadership positions in the biotechnology industry including: CEO, Pinteon Therapeutics; CEO, Theracrine; CCO, BioVex; CEO, Innovive Pharmaceuticals; as well as various commercial and manufacturing roles at Sanofi, IDEC Pharmaceuticals and Amgen.

Steve holds a BS from the University of Oregon and an MBA from Cornell University.

Related Story

Appointments

 Carisma Therapeutics Announces Appointment Of Michael Klichinsky

Carisma Therapeutics Announces Appointment Of Michael Klichinsky, PharmD, PhD, As Chief Scientific Officer

April 26 2022

Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, […]